Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) gapped up prior to trading on Monday . The stock had previously closed at $0.11, but opened at $0.25. Eyegate Pharmaceuticals shares last traded at $0.31, with a volume of 5343509 shares.

The company has a market capitalization of $15.18 million, a PE ratio of -1.03 and a beta of 2.19.

In other Eyegate Pharmaceuticals news, major shareholder Armistice Capital Master Fund purchased 549,647 shares of the firm’s stock in a transaction on Friday, March 29th. The shares were purchased at an average price of $0.32 per share, for a total transaction of $175,887.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 43.90% of the stock is owned by insiders.

A hedge fund recently raised its stake in Eyegate Pharmaceuticals stock. Virtu Financial LLC boosted its holdings in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 465.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,391 shares of the specialty pharmaceutical company’s stock after buying an additional 56,299 shares during the period. Virtu Financial LLC owned about 0.16% of Eyegate Pharmaceuticals worth $32,000 as of its most recent SEC filing. 40.10% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Eyegate Pharmaceuticals (EYEG) Shares Gap Up to $0.25” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/eyegate-pharmaceuticals-eyeg-shares-gap-up-to-0-25/3030594.html.

About Eyegate Pharmaceuticals (NASDAQ:EYEG)

EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.

Recommended Story: Beta

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.